within Pharmacolibrary.Drugs.ATC.L;

model L01EE02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.463,
    Cl             = 3.833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,
    adminCount     = 1,
    Vd             = 0.104,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004033333333333333,
    Tlag           = 22.2,            
    Vdp             = 0.177,
    k12             = 91.6,
    k21             = 91.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>ATC code:</td><td>L01EE02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cobimetinib is an oral, selective inhibitor of MEK1 and MEK2, which are components of the MAPK/ERK pathway. It is primarily used in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation. Cobimetinib is approved by the FDA and EMA for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced solid tumors, primarily metastatic melanoma. Data represent population PK results following multiple oral doses.</p><h4>References</h4><ol><li><p>Lieu, CH, et al., &amp; Tabernero, J (2017). A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. <i>The oncologist</i> 22(9) 1024â€“e89. DOI:<a href=\"https://doi.org/10.1634/theoncologist.2017-0175\">10.1634/theoncologist.2017-0175</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28592615/\">https://pubmed.ncbi.nlm.nih.gov/28592615</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end L01EE02;
